Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 885-892

  Sturgeon, Christopher M ^a   Knight, Zachary A ^b   Shokat, Kevan M ^b   Roberge, Michel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMA 37; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA; DNA DEPENDENT PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL KILLING; CELL SURVIVAL; CHO CELL; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DNA DAMAGE; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; G2 PHASE;

EID: 33646589980     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0358     Document Type: Article

References (48)

1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
2. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
3. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003;4:712-20.
4. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001;477:131-53.
5. Takata M, Sasaki MS, Sonoda E, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand breaks. EMBO J 1998;17:5497-508.
6. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
7. 2 DNA damage checkpoint and their potential for cancer therapy. In: Meijer L, Jezequel A, Roberge M, editors. Prog Cell Cycle Res. Vol. 5. Roscoff (France): Editions "Life in Progress"; 2003. p. 423-30.
8. Kashishian A, Douangpanya H, Clark D, et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2003;2:1257-64.
9. Shinohara ET, Geng L, Tan J, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005;65:4987-92.
10. Ding Q, Reddy YVR, Wang W, et al. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Mol Cell Biol 2003;23:5836-48.
11. Fan S, Smith ML, Rivet DJ, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-54.
12. Anderson HJ, Coleman JE, Andersen RJ, Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A, hemiasterlin B. induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 1997;39:223-6.
13. 2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998;58:5701-6.
14. 2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem 2001;276:17914-9.
15. 2 DNA damage checkpoint inhibition and antimitotic activity of 13-hydroxy-15-oxozoapatlin. J Biol Chem 2001;276:48231-6.
16. Senderowicz AM, Lahusen T. Assays for cyclin-dependent kinase inhibitors. In: Buolamwini JK, Adjei AA, editors. Novel anticancer drug protocols. Vol. 85. Totowa (NJ): Humana Press, Inc.; 2003. p. 39-48.
17. Chaturvedi P, Eng WK, Zhu Y, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047-54.
18. Sarkaria JN. Identifying inhibitors or ATM and ATR kinase activities. In: Buolamwini JK, Adjei AA, editors. Novel anticancer drug protocols. Vol. 85. Totowa (NJ): Humana Press; 2003. p. 49-56.
19. 2 checkpoint after ionizing radiation. Cancer Res 2002;62:6031-4.
20. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-82.
21. 2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J Biol Chem 2000;275:10342-8.
22. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
23. 2 DNA damage checkpoint inhibitor isogranulatimide. Mol Cancer Ther 2004;3:1221-7.
24. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003;1:913-20.
25. Knight ZA, Chiang GG, Alaimo PJ, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorphine scaffold. Bioorg Med Chem 2004;12:4749-59.
26. Mercer WE. Cell cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr 1992;2:251-63.
27. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82.
28. Allalunis-Turner MJ, Barron GM, RS Day I, Dobler KD, Mirzayans R. Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res 1993;134:349-54.
29. Hoppe BS, Jensen RB, Kirchgessner CU. Complementation of the Radiosensitive M059J Cell Line. Radiat Res 2000;153:125-30.
30. Lees-Miller SP, Godbout R, Chan DW, et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995;267:1183-5.
31. Chan DW, Gately DP, Urban S, et al. Lack of correlation between ATM protein expression and tumour cell radiosensitivity. Int J Radiat Biol 1998;74:217-24.
32. Gately DP, Hittle JC, Chan GKT, Chen TJ. Characterization of ATM expression, localization, and associated DNA-dependent protein kinase activity. Mol Biol Cell 1998;9:2361-74.
33. Tsuchida R, Yamada T, Takagi M, et al. Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon in yeast. Radiat Res 2002;158:195-201.
34. 2-phase checkpoint in cells of a human cell line lacking DNA-dependent protein kinase activity. Radiat Res 1997;147:284-7.
35. Anderson CW, Allalunis-Turner MJ. Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. Radiat Res 2000;154:473-6.
36. Li Z, Otevrel T, Gao Y, et al. The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 1995;83:1079-89.
37. Blunt T, Finnie NJ, Taccioli GE, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 1995;80:813-23.
38. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 2004;64:2390-6.
39. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998;282:1893-7.
40. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39.
41. 2/M DNA damage checkpoint. Genes Dev 2000;14:1448-59.
42. 2/M checkpoints are induced by ionizing radiation. Mol Cell Biol 2002;22:1049-59.
43. d' Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-8.
44. Stronati L, Gensabella G, Lamberti C, et al. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer 2001;92:2484-92.
45. Wilson CR, Davidson SE, Margison GP, Hendry SPJH, West CM. Expression of Ku70 correlates with survival in carcinoma of the cervix. Br J Cancer 2000;83:1702-6.
46. Rigas B, Borgo S, Elhosseiny A, et al. Decreased expression of DNA-dependent protein kinase, a DNA repair protein, during human colon carcinogenesis. Cancer Res 2001;61:8381-4.
47. Eriksson A, Lewensoh R, Larsson R, Nilsson A. DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res 2002;22:1787-93.
48. Friesland S, Kanter-Lewensohn L, Tell R, Munck-Wikland E, Lewensohn R, Nilsson A. Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy. Head Neck 2003;25:313-21.